Synopsys Study Shows Open Source Security Top-of-Mind but Patching Too Slow

Global survey of 1,500 IT professionals finds that 40% of respondents worldwide had delivery schedules disrupted to address open source vulnerabilities

PR Newswire

MOUNTAIN VIEW, Calif., Dec. 8, 2020 /PRNewswire/ — Synopsys, Inc. (Nasdaq: SNPS) today released the report, DevSecOps Practices and Open Source Management in 2020. Produced by the Synopsys Cybersecurity Research Center (CyRC), the report highlights the findings from a survey of 1,500 IT professionals working in cyber security, software development, software engineering, and web development. The report explores the strategies that organizations around the world are using to address open source vulnerability management as well as the growing problem of outdated or abandoned open source components in commercial code.

Open source plays a critical role in today’s software ecosystem. The overwhelming majority of modern codebases contain open source components, with open source often comprising 70% or more of the overall code. Yet paralleling the growth of open source use is the mounting security risk posed by unmanaged open source. In fact, according to the 2020 OSSRA report, 75% of the codebases audited by Synopsys contain open source components with known security vulnerabilities. To combat this situation, respondents to the survey cite identification of known security vulnerabilities as the number one criterion when vetting new open source components.

“It’s clear that unpatched vulnerabilities are a major source of developer pain, and ultimately business risk.” said Tim Mackey, principal security strategist of the Synopsys Cybersecurity Research Center. “The ‘DevSecOps Practices and Open Source Management in 2020’ report highlights how organizations are struggling to effectively track and manage their open source risk.”

“Over half—51%—say it takes two to three weeks for them to apply an open source patch,” Mackey continued. “This is likely tied to the fact that only 38% are using an automated software composition analysis (SCA) tool to identify which open source components are in use and when updates are released. The remaining organizations are probably employing manual processes to manage open source—processes that can slow down development and operations teams, forcing them to play catch-up on security in a climate where, on average, dozens of new security disclosures are published daily.”

Other noteworthy findings in the “DevSecOps Practices and Open Source Management in 2020” report include:

  • DevSecOps is rapidly growing worldwide. A combined 63% of respondents reported that they are incorporating some measure of DevSecOps activities into their software development pipelines.
  • There is no universally adopted application security testing (AST) tool. As the responses to the survey questions indicate, there is no shortage of application security testing tools and techniques. However, even the AST tool with the highest adoption rate is still only utilized by less than half of respondents.
  • The media plays an important role in open source risk management. Forty-six percent of respondents noted that media coverage had prompted their organization to apply more stringent controls on open source usage.
  • Forty-seven percent of respondents are defining standards around the age of open source components they use. A growing issue in the open source community is project sustainability. A 2020 Synopsys study showed that 91% of codebases audited in 2019 contained open source components that either were more than four years out of date or had no development activity in the past two years. Security risks increase when obsolete code is deployed, including the threat of an open source component being hijacked. Such a situation occurred in 2018 when the event-stream component was hijacked to target Bitcoin in Copay accounts.

To learn more, download a copy of the DevSecOps Practices and Open Source Management in 2020 report.

About the Synopsys Software Integrity Group

Synopsys Software Integrity Group helps development teams build secure, high-quality software, minimizing risks while maximizing speed and productivity. Synopsys, a recognized leader in application security, provides static analysis, software composition analysis, and dynamic analysis solutions that enable teams to quickly find and fix vulnerabilities and defects in proprietary code, open source components, and application behavior. With a combination of industry-leading tools, services, and expertise, only Synopsys helps organizations optimize security and quality in DevSecOps and throughout the software development life cycle. Learn more at www.synopsys.com/software.

About Synopsys

Synopsys, Inc. (Nasdaq: SNPS) is the Silicon to Software™ partner for innovative companies developing the electronic products and software applications we rely on every day. As the world’s 15th largest software company, Synopsys has a long history of being a global leader in electronic design automation (EDA) and semiconductor IP and is also growing its leadership in software security and quality solutions. Whether you’re a system-on-chip (SoC) designer creating advanced semiconductors, or a software developer writing applications that require the highest security and quality, Synopsys has the solutions needed to deliver innovative, high-quality, secure products. Learn more at www.synopsys.com.

 

Editorial Contact:

Mark Van Elderen

Synopsys, Inc.
650-793-7450
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/synopsys-study-shows-open-source-security-top-of-mind-but-patching-too-slow-301188351.html

SOURCE Synopsys, Inc.

Appian RPA Receives FedRAMP Certification

Government and Defense Organizations can now adopt Cloud RPA and Meet Rigorous Standards for Security, Compliance and Scalability, available direct from Appian

PR Newswire

MCLEAN, Va., Dec. 8, 2020 /PRNewswire/ — Appian (NASDAQ: APPN) today announced at its 4th annual AppianGovernment conference that Appian RPA has achieved authorization from the Federal Risk and Authorization Management Program (FedRAMP) as part of Appian Cloud. Appian RPA is a new component of the Appian low-code automation platform and joins Appian’s existing FedRAMP authorization and Agency Authority to Operate (ATO) accreditation for the Appian Cloud.

“Intelligent Automation combines robotic process automation (RPA), intelligent business management software (iBPMS) and Artificial Intelligence (AI) together to automate, simplify, discover, design, measure and manage workflows and processes across the enterprise,” said Kirke Everson, Principal, Intelligent Automation, Government, KPMG. “Appian’s announcement means Federal agencies can leverage the power of a tightly coupled low-code automation platform and RPA bots to provide a quicker time value for agencies to realize intelligent automation under one ATO.”

Appian’s secure architecture complies with federal standards and certifications including FISMA, FedRAMP, HIPAA, SOC 2, and SOC 3. Infrastructure options for Appian’s federal customers include a FedRAMP Authorized Cloud, fully managed IL4 and IL5 services, MilCloud, AWS GovCloud, and Microsoft Azure.

“While Cloud-first is the accepted strategy for federal agencies today, desktop installations of RPA have sprouted up everywhere merely because there were no good Cloud RPA alternatives,” said Mike Beckley, founder and CTO of Appian. “Appian isn’t the first RPA but is among the first of a new generation of Cloud-native RPA solutions that check-off every item on a CIO’s wishlist: speed, security, scalability, availability, governance, and most of all, cost-effectiveness.”

Appian works with more than 100 government organizations worldwide, including 10 of 14 U.S. Civilian cabinet level agencies and all four branches of the military.

To learn more visit https://www.appian.com/industries/government-public-sector/

About Appian
Appian provides a low-code automation platform that accelerates the creation of high-impact business applications.  Many of the world’s largest organizations use Appian applications to improve customer experience, achieve operational excellence, and simplify global risk management and compliance.

Cision View original content:http://www.prnewswire.com/news-releases/appian-rpa-receives-fedramp-certification-301186905.html

SOURCE Appian

Five9 CEO Rowan Trollope Named Top Executive for Cloud Computing in 2020 by Stratus Awards

Five9 CEO Rowan Trollope Named Top Executive for Cloud Computing in 2020 by Stratus Awards

SAN RAMON, Calif.–(BUSINESS WIRE)–
The Business Intelligence Group today announced that it has named Rowan Trollope, CEO of Five9 (NASDAQ:FIVN), Top Executive in Cloud Computing in the 2020 Stratus Awards. Stratus Awards is an annual business awards program that recognizes companies, products and people that are offering unique solutions that leverage cloud technologies.

Five9 is a leading provider of intelligent cloud contact center software, providing end-to-end solutions with digital engagement, workforce optimization, analytics, workflow automation and artificial intelligence to increase agent productivity and deliver tangible business results. Trollope has led the company since joining as CEO in May 2018.

“I am honored to be awarded the title of Top Executive in this year’s Stratus Awards for Cloud Computing,” said Rowan Trollope, Five9 CEO. “In a year where cloud technology has never been more vital to business continuity and success, this win is a testament to our vision and commitment to our customers, and recognizes the dedicated Five9 team that I am proud to lead.”

“Rowan Trollope and Five9 are at the forefront of the cloud helping to drive practical innovations in the cloud,” said Maria Jimenez, Chief Nominations Officer of Business Intelligence Group. “The cloud is now part of the fabric of our personal and professional lives and we are thrilled that our judges were able to help promote all of these innovative services, organizations and executives.”

AboutFive9

Five9 is a leading provider of cloud contact center software for the intelligent contact center space, bringing the power of cloud innovation to customers and facilitating more than six billion call minutes of customer engagements annually. Five9 provides end-to-end solutions with omnichannel routing, analytics, WFO and AI to increase agent productivity and deliver tangible business results. The Five9 Genius platform is reliable, secure, compliant and scalable; designed to create exceptional, personalized customer experiences.

For more information, visit www.five9.com.

Engage with us @Five9, LinkedIn, Facebook, Blog, That’s Genius Podcast.

About Business Intelligence Group

The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry and business award programs, business executives—those with experience and knowledge—judge the programs. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

Five9

Kendall Taylor

925-231-2196

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Logo
Logo

ibi and Atos Partner to Build Cloud-based Data and Analytics Environment for Healthcare Providers

New Facility Collaboration Population Screening system will provide real-time access to intestinal, cervical, and breast cancer data

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Information Builders, Inc. (ibi), a leading end-to-end data and analytics software company, today announced that it is partnering with Atos, a global leader in digital transformation, to create a cloud-based healthcare system offering real-time access to combined data from intestinal, cervical, and breast cancer studies.

The services will include project management, a data warehouse, and reports to support a Dutch population screening cooperative, De Facilitaire Samenwerking Bevolkingsonderzoeken (FSB), in the move from traditional to self-service business intelligence (BI) and decision-making using ibi’s modern data and analytics platform.

FSB, focused on information technology, information management, contract management, and joint procurement, will use the new healthcare system to support data analytics on behalf of five population screening organizations.

“FSB is looking to improve operational efficiency, provide better data analysis, and support greater predictability of trends in the field through real-time access to data from screening examinations,” said Brian Doheny, senior vice president, Global Sales and Channel at ibi. “The new cloud-based data and analytics system we are building with Atos will allow the cooperative to achieve these goals and make better predictions based on combined data from multiple population studies.”

ibi, Atos, and FSB will use the new Facility Collaboration Population Screening system to support improved cancer healthcare in the Netherlands.

“FSB considers itself a proud partner in cancer screening and is focused on adding value for the five screening organizations it supports in the Netherlands. To do this, they need to be more data-driven, leveraging the most complete set of study data,” said Peter ‘t Jong, CEO, Atos Northern Europe. “The business intelligence solution we are developing with ibi will support this worthy commitment.”

ibi’s modern data and analytics platform provides organizations with the ability to turn all types of data into actionable insights for real business outcomes. Powered by ibi Cloud, customers gain the speed, cost savings, and flexibility that is crucial for today’s business needs while driving innovation via cloud-native technology. Whether in the ibi Cloud or private cloud, either fully managed or self-managed, ibi products and services deliver leading-edge capabilities to unlock growth through better data and analytics.


See how ibi
empowers data-first healthcare organizations.



Tweet This:


.@infobldrs and @Atos partner to build #cloud-based #data and #analytics environment for #healthcare providers. Get the details:


https://bit.ly/36WNDi9

About Atos

Atos is a global leader in digital transformation with 110,000 employees in 73 countries and annual revenue of EUR 12 billion. Number one in Europe in Cloud, Cybersecurity and High-Performance Computing, the Group provides end-to-end Orchestrated Hybrid Cloud, Big Data, Business Applications and Digital Workplace solutions. The Group is the Worldwide Information Technology Partner for the Olympic & Paralympic Games and operates under the brands Atos, Atos|Syntel, and Unify. Atos is a SE (Societas Europaea), listed on the CAC40 Paris stock index.

The purpose of Atos is to help design the future of the information technology space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

About ibi

ibi is a data and analytics software company that embeds intelligence into ― everything. From the beginning, ibi has known the importance of data and insights to make better decisions. We help organizations get their complex and disconnected data in order, so they can build, embed, and automate intelligence in everything they do. By preparing organizations for the future and turning them into builders ― information builders, everyone can use enterprise-trusted data at scale to drive their growth. Whether our customers use pre-built applications or build their own solutions for their data and analytics challenges, ibi powers their innovation and reinvention. ibi’s open platform and industry-specific building blocks accelerate speed-to-market, improve operational efficiency, and enhance their customers’ experience.

Visit us at ibi.com, follow us on Twitter, like us on Facebook, and visit our LinkedIn page.

Press Contacts

Michael Kornspan
Information Builders
(917) 339-5734
[email protected]

Holly Langbein
Highwire PR
(916) 769-2199
[email protected]



PyroGenesis’ Board Approves Plan to File Application to NASDAQ for Q1 2021 Listing

MONTREAL, Dec. 08, 2020 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQB: PYRNF) (FRA: 8PY), (the “Company”, the “Corporation” or “PyroGenesis”) a Company that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce today that at the Company’s Board of Directors’ (the “Board”) meeting on December 7th, 2020, it was formally approved to move forward with the strategic decision to file an application to list its common shares (“Shares”) on the NASDAQ Stock Exchange (“NASDAQ”) over the next several days. NASDAQ is the second largest exchange by market capitalization worldwide, and is home to many of the world’s best technology companies.

The Company has engaged Nelson Mullins Riley & Scarborough LLP as its US legal counsel to process the NASDAQ listing, and the Company’s external Canadian legal counsel will provide the required oversight during this process.

“We are pleased to announce today another significant step towards ultimately enhancing shareholder value,” said Mr. P. Peter Pascali, CEO and Chair of PyroGenesis. “The United States has the largest capital market in the world and, as such, a NASDAQ listing has always been on our radar as one of the many strategies to execute as part of our long-term vision for the Company. On the back of our recent achievements, and our successful uplisting to the Toronto Stock Exchange (“TSX”), the Board decided that the timing was right to proceed with this application. After discussions with our US legal counsel, and a representative of NASDAQ, it was confirmed that the Company meets the standard requirements for a listing. However, there still remains a rigorous application procedure which the Company must pass before a final listing is granted. The listing, barring any delays or objections, is expected before the end of Q1 2021.”

There will not be a concurrent financing associated with this listing nor will there be a reverse stock split.

“A NASDAQ listing is a natural next step for the Company,” said Ms. Rodayna Kafal, VP IR/Comms and Strategic BD. “We believe a NASDAQ listing should, amongst other things, (i) provide additional opportunities to attract institutional and retail investors, thus allowing the Company to further broaden its investor base, and (ii) increase the visibility and credibility of the Company worldwide thereby attracting additional sales, partnerships, and M&A opportunities.”

In advance of an anticipated listing on NASDAQ, PyroGenesis will, over the next several days, formally file an application to list on NASDAQ. Shortly thereafter, the Company will file a 40-F registration statement with the United States Securities and Exchange Commission (SEC). The listing of the Company’s Shares on NASDAQ remains subject to the approval of the exchange, and the satisfaction of all applicable listing and regulatory requirements. The Company will continue to maintain the listing of its Shares on the TSX and, subsequent to a successful listing, would trade on both exchanges under the ticker symbol “PYR”.

About PyroGenesis Canada Inc
.

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks
detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at


www.sedar.com

, or at www.otcmarkets.com.Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:
Rodayna Kafal, Vice President, IR/Comms. and Strategic BD
Phone: (514) 937-0002, E-mail: [email protected]

RELATED LINK: http://www.pyrogenesis.com/



Interface shares its top security industry predictions for 2021

Earth City, MO, Dec. 08, 2020 (GLOBE NEWSWIRE) —  Interface Security Systems, a leading managed service provider delivering business security, managed network, UCaaS and business intelligence solutions to distributed enterprises, today shared its top predictions for the physical security industry.

 

1.         2021: Slow beginning followed by biggest demand shock

2021 could prove to be almost as turbulent for the security industry as 2020. In the earlier part of the year, we expect the industry will continue to grapple with the fallout from COVID-19 with possible disruptions to the equipment supply chain. However, assuming we can keep our critical workforce healthy and an effective vaccine is successfully deployed in Q2, the situation could improve very quickly. If restaurants, retailers, sporting/entertainment venues reopen en masse, and formerly vacant commercial buildings fill back up with workers in late Q2 and early Q3, the new challenge, particularly for systems integrators, will be to keep pace with the pent up demand. The reopening of America will require the deployment of unprecedented security resources, from servicing and refreshing existing systems to the deployment of new solutions. The second half of 2021 could set the stage for the biggest demand shock the security industry has ever experienced.

 

2.         Yesterday’s security camera has finally become today’s intelligent sensor

While the security industry’s initial foray into analytics is largely over-promised and under-delivered, today’s artificial intelligence (AI) and machine learning are about to fundamentally change the core value proposition of the physical security industry. Security technology is no longer seen as devices to keep people and property safe, but it is finally becoming a strategic tool to help improve business operations. AI-based security solutions and cameras are now able to go beyond security to capture valuable marketing and sales transaction data, analyzing customer patterns and behavior. AI enables us to “see” in new ways. It’s impossible for humans to consume and accurately monitor the vast amount of video streams and other data available at most businesses, so AI is arriving at a time when we need it the most. AI can take otherwise unmanageable reams of data, and turn it into actionable information. And that is nothing short of revolutionary for our industry. The applications are limitless, and the ultimate beneficiary will be the customer. And at a time when organizations are having to be efficient with their budgets, it’s never been more important that the investment they’re making in their security systems should allow them to improve their overall business operations.

 

3.         Privacy concerns need to be taken seriously

As cameras become increasingly more powerful and feature-rich, their ability to capture personal identifying information (PII) continues to grow. In 2021, the security industry along with Congress will begin in earnest to tackle the privacy implications of AI in general, and facial recognition technologies in particular. The patchwork of regulations at the state and local level is confusing and increasingly difficult to manage. The status quo risks stunting technology investment and putting us far behind advancements in other countries. We need to strike a balance between innovation and privacy so facial recognition and other biometrics security technologies can flourish safely without compromising the privacy of individuals. As long as a privacy-by-design approach is taken –where privacy features and functionality are built into the core design from inception and not simply an afterthought — there is no reason to slow the development of useful and exciting technologies like AI, face recognition, and others.

  

4.         Residential security providers to target the commercial sector

2021 could be the year the large, new security solution manufacturers set their sights on commercial security integrators and their customers. New entrants have essentially taken over the residential security space with slick new applications and easy DIY installs. They will seek out new markets. However, businesses should not be tempted to trade cybersecurity for the convenience and cost of these solutions. The complex technology requirements to develop safe IoT devices that are designed to effectively protect a commercial organization’s entire network from possible cyber-attacks are not the same as what is required for a residential application. Commercial security integrators should prepare to demonstrate the unique value they bring to the table, and/or partner with these new entrants to ensure the necessary steps are taken to protect their customers’ businesses. 

5.         2021 could be the year security teams get a seat in the C-suite

The security industry has been challenged in unpreceded ways during the pandemic and security professionals were pulled into the forefront during this crisis. Our industry’s entire business is based on planning for the unexpected. Security leaders have shown extraordinary resilience and resourcefulness evidenced by so many of our customers quickly adapting to the new needs and challenges posed by the situation. They have been able to repurpose and adapt their business models and leverage their existing security infrastructure to meet some of the new challenges created by the pandemic with video analytics such as people counting, occupancy management, ensuring mask-wearing guidelines are being observed, and so much more. This crisis has given the security industry an opportunity to redefine its role and value proposition. By leveraging business and operational intelligence data that can pay for itself and directly affect the profitability of the organization, the security industry is on the cusp of morphing from a tactical application to a truly strategic enterprise-shaping role.

  

About Interface Security Systems

Interface Security Systems is a leading managed services provider delivering business securitymanaged network,UCaaS and business intelligence solutions to distributed enterprises. We improve security, streamline connectivity, optimize operations, and reduce IT costs, maximizing ROI for the nation’s top brands. Learn more and follow us on our blog Making IT Happen and on LinkedIn.

 

Attachments



Veronique Froment
Interface Security Systems
603-537-9248
[email protected]

Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors

Cytovia to present at RBC Capital Market Healthcare Conference on December 16, 2020

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Cytovia Therapeutics, an emerging NK cell therapeutics company, announced today that it plans to file with the FDA in 2021 an Investigational New Drug (IND) application and initiate clinical trials in hematological and solid tumors with its Universal iPSC NK cell therapy (U-iNK).

Cytovia’s CEO, Dr. Daniel Teper commented: “Cytovia is among a select group of biotech companies developing Gene Edited iPSC NK and CAR NK cell therapeutics. We are aiming to be, in 2021, the second company to initiate clinical trials with an iPSC NK product. We are enthusiastic about the potential of U-iNK to prevent relapse in Acute Myeloid Leukemia, and in combination with PD1/ PDL-1 inhibitors and our own NK engager bispecific antibodies, to improve outcomes in solid tumors starting with hepatocellular carcinoma.”

Cytovia will participate in the RBC Capital Markets Healthcare Private Company Conference on December 15-16, 2020. Daniel Teper, PharmD, CEO, Wei Li, PhD, CSO and Kaouthar Lbiati, MD, VP, Product Strategy will take part in a Fireside chat with RBC’s Senior Analyst, Gregory Renza, MD, on December 16, 2020 at 10am ET. A link to the discussion will be available on Cytovia’s website and social media channels.

About Cytovia Therapeutics
Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, INSERM, and CytoImmune Therapeutics.

Learn more at www.cytoviatx.com and follow Cytovia Therapeutics on Social Media FacebookLinkedInTwitter, Youtube

For more information
,
please contact:

Cytovia Therapeutics, Inc
Sophie Badré
Vice President, Corporate Affairs
[email protected] 
Cell: 1 (929) 317 1565 

Anna Baran-Djokovic

Vice President, Investor Relations
[email protected]
VP Investor Relations
Cell: +44 7521083006



This Season, T-Mobile Rings in Holiday Cheer with Virtual Visits from Santa Claus

This Season, T-Mobile Rings in Holiday Cheer with Virtual Visits from Santa Claus

What’s the news: T-Mobile is giving kids the chance to visit Santa Claus … virtually! Starting Thursday, December 10, head to SantaCalling.com to schedule a free, live video chat with Santa. You’ll get the video afterwards to share the joy with family and friends.

Why it matters: Visiting Santa is a memorable holiday tradition for families, but in-person visits may not be possible for everyone this year. That’s why the Un-carrier is giving everyone — not just customers — the chance to chat with ol’ Saint Nick from the comfort of their couch, ensuring a safe and merry holiday greeting.

Who it’s for: Kids around the country in need of Christmas cheer.

BELLEVUE, Wash.–(BUSINESS WIRE)–
Ahem. A holiday poem, from your T-Mobile fam.

COVID’s got us home-bound

At Christmastime this year

But fear not, all you Santa fans…

The Un-carrier is here!

T-Mobile’s gifting families

FREE virtual Santa chats

So gather the kids and wish lists

And don those fuzzy red hats

Forget the lines and waiting

This year, Santa’s coming to YOU

And for the Santa-lap-weary,

It’s a lot less scary, too

It’s free no matter who you’re with

T-Mobile, grinchy Verizon, or even AT&T…

‘Cause EVERYONE deserves some joy

This year, especially.

T-Mobile (NASDAQ: TMUS) is putting the HO-HO in HOME this year, keeping Santa connected with kids across the country through the magic of a real-time video call, all the way from the North Pole. Starting Thursday, Dec. 10 through Wednesday Dec. 23, anyone — yep, even Verizon and AT&T customers! — can schedule a free video call with Santa on SantaCalling.com. And, you’ll get a video of your Santa chat, so you can revisit the memory and share it with friends and family. Even Santa’s time is limited — especially this time of year, but if his schedule looks booked, don’t worry … more time slots will open daily at 9 a.m. PT.

“Holiday celebrations will look a little different this year … but T-Mobile is making sure the kids can still visit Santa, this time from the comfort of home,” said Mike Sievert, CEO of T-Mobile. “Cozy up with your loved ones, swap Santa’s lap for a laptop and get ready for a personal chat with the big guy. Merry Christmas from your T-Mobile fam!”

Here’s how to sign up:

  1. Starting December 10, head to SantaCalling.com and select your time slot — if there aren’t more available, check back at 9 a.m. PT the next day! You’ll have the option to request a Santa that best suits your family.
  2. Check your email for your confirmation, then mark your calendar! You’ll also get a link to join your video call directly.
  3. Following your virtual visit, you’ll receive an email with a link to download your video.
  4. Then, post your visit on social using #HolidayOn to share with family and friends!

Plus, be sure to follow @TMobile on Twitter, share your kiddo’s wish list with #HolidayOn and @TMobile because Santa’s always watching, and be on the lookout for the #iLoveTMobile Holiday Sweepstakes from Friday, Dec. 18 through Tuesday, Dec. 22.

For more information, visit www.SantaCalling.com starting Thursday, Dec. 10. Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.

Santa Calling: Limited slots available; first-come, first-serve. Free Zoom account required. Must be parent or guardian 18+ to enter. For more info visit SantaCalling.com. Sweepstakes: NO PURCHASE NECESSARY. Open to residents of 50 US, PR, DC 18+. 9 AM ET 12/18/20-5:59 PM ET 12/22/20. Void where prohibited. Sponsored by T-Mobile. For full rules & how to enter (available on 12/18) visit: https://www.ilovetmobileholidaysweepstakes.com/rules.

About T-Mobile

T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.

Media Contacts

T-Mobile US, Inc. Media Relations

[email protected]

Investor Relations Contact

T-Mobile US, Inc.

[email protected]

https://investor.t-mobile.com

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Consumer Electronics Technology Other Retail Online Mobile Entertainment Events/Concerts Family Other Entertainment Mobile/Wireless Consumer Retail Parenting Entertainment Children Public Relations/Investor Relations General Entertainment Communications Telecommunications Networks Internet

MEDIA:

Logo
Logo

Trex® Cladding™ Captures Spot on Building Design + Construction’s List of “Top 75 Products” for 2020

WINCHESTER, Va., Dec. 08, 2020 (GLOBE NEWSWIRE) — Trex®, the world’s #1 brand of wood-alternative decking and railing and leader in high-performance, low-maintenance outdoor living products, is ending the year with acclaim. The company’s Trex® Cladding product has earned a coveted spot on Building Design + Construction’s annual list of “Top 75 Products,” based on its high engagement rate among the magazine’s audience of architects, engineers and contractors over the past 12 months.

“This recognition is particularly meaningful because it reinforces Trex as a preferred brand among building and design professionals in both the residential and commercial sectors,” said Adam Zambanini, president of Trex Residential Products. “The premium aesthetic and ultra-low maintenance of our rainscreen cladding product have definitely attracted the attention of architects and business owners, which has enabled us to seamlessly expand our footprint in the commercial building arena.”

Designed to make hardwood planks obsolete in modern rainscreen systems, Trex Cladding is made from the company’s industry-leading Trex Transcend® deck boards and can be applied vertically or horizontally to lend a modern look to any structure. The open-joint façade system promotes airflow while providing a worry-free armor with visual appeal.

Available in three board lengths and a variety of color options, Trex Cladding features a proprietary nine-element surface formulation that produces a natural, wood-like grain pattern with a durable and resilient finish. Unlike wood, Trex Cladding boards resist fading, staining, scratching and mold – and won’t rot, warp, crack or splinter. No sanding, staining or sealing are ever needed. Just an occasional soap and water cleaning will keep boards looking like new for decades. Furthermore, the product is backed by a 25-year Fade and Stain Warranty for both residential and commercial projects.

“Rainscreen cladding is extremely popular right now across the building industry and has proven to be a natural extension for us,” noted Zambanini. “The unparalleled performance attributes of our Trex Transcend boards make them ideally suited to outperform wood in these applications.”

Adding to its appeal, Trex Cladding is made from 95% recycled materials and is easy to install using conventional tools and methods. Boards are approved for 24-inch on-center furring strip spacing, which means faster installation and lower installed costs. Additionally, the highly impact- and scratch-resistant material is tested to withstand hurricane-force winds and is code compliant for all Type V-B structures under 40 feet in height.

This recognition by Building Design + Construction complements a number of other accolades that have been presented to Trex this year, including:

More information about Building Design + Construction’s list of “Top 75 Products” can be found here. To learn more about Trex Cladding and the entire Trex product portfolio, visit www.trex.com.


About Trex Company


Trex Company, Inc. [NYSE: TREX] is the world’s largest manufacturer of high performance wood-alternative decking and railing, with more than 25 years of product experience. The #1 brand in outdoor living is proud to be named one of the 2020 100 Fastest-Growing Companies by Fortune magazine. Stocked in more than 6,700 retail locations worldwide, Trex outdoor living products offer a wide range of style options with fewer ongoing maintenance requirements than wood, as well as a truly environmentally responsible choice. For more information, visit trex.com. You also can follow Trex on Twitter (@Trex_Company), Instagram (@trexcompany), Pinterest (trexcompany) or Houzz (trexcompany-inc), “like” Trex on Facebook (@TrexCompany) or view product and demonstration videos on the brand’s YouTube channel (TheTrexCo).

Contact: Nicholas Heim or Sara Tatay
L.C. Williams & Associates
615/678-2114 or 312/565-4612
[email protected] or [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a0aa2cce-665a-45f6-bf5c-34ca0d2b6443



Natera to Present New Immunotherapy Monitoring Data at SABCS 2020

Two new studies in breast cancer demonstrate potential of Natera’s technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms

PR Newswire

SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ — Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, Signatera,™ at the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) taking place December 8-11, 2020. 

Natera will present two posters: one from the I-SPY2 Trial describing Signatera’s performance as a predictive biomarker for response to neoadjuvant immunotherapy, and the other from the Beyond BRCA study describing Natera’s plasma-based whole exome analysis as a tool for tracking clonal evolution and discovering new treatment resistance mutations.

Details about the presentations are as follows:

Poster #PD9-02 | Spotlight Poster Discussion

Presenter: Mark Jesus M. Magbanua, Ph.D.

Date: Dec 10, 2020 | 3:30 PM to 4:45 PM CT

Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer treated with neoadjuvant chemotherapy (NAC), with or without pembrolizumab

A study from the prospective, randomized I-SPY2 Trial exploring the predictive value of personalized ctDNA analysis, performed by Natera, in patients with early-stage breast cancer undergoing either standard NAC or NAC in combination with the immune checkpoint inhibitor pembrolizumab. Early clearance of ctDNA (three weeks after initiation of treatment) is significantly associated with achieving pathological complete response, and may serve as an early surrogate marker for response to therapy. Persistent presence of ctDNA after completion of NAC, but prior to surgery, is strongly correlated with poor disease-free survival.

“Just last week, the I-SPY investigators published a paper in Annals of Oncology validating Signatera’s performance in neoadjuvant treatment monitoring for patients with early-stage breast cancer,” said Angel Rodriguez, M.D., Medical Director at Natera. “This new study presented at SABCS follows a different cohort of I-SPY2 patients who received NAC in combination with immunotherapy. The results from this new cohort further validate the initial finding that Signatera can be a powerful tool for neoadjuvant treatment response monitoring, regardless of the type of therapy, and can complement existing tools, such as pathology and imaging, to optimize decisions around the escalation or de-escalation of treatment.” 

Poster #PD10-12 | Spotlight Poster Discussion

Presenter: Joshua J. Gruber, M.D., Ph.D.

Date: Dec 11, 2020 | 1:00 PM to 2:15 PM CT

Genomic analysis from the Talazoparib Beyond BRCA clinical trial: homologous recombination deficiency (HRD) scores, loss-of-heterozygosity and mutations in non-BRCA 1/2 mutant tumors

A poster on the genomic characterization of treatment response and resistance to the PARP1 inhibitor, talazoparib, in non-BRCA 1/2 mutant tumors with mutations in other HRD-associated genes. Plasma-based whole exome sequencing of ctDNA, performed by Natera, provides a comprehensive view of tumor evolution over the course of treatment, wherein responders and nonresponders show distinct patterns, leading to the identification of novel mutations responsible for acquired resistance to talazoparib treatment.

“Drug resistance remains a significant challenge in the management of breast cancer,” said Joshua J. Gruber, M.D., Ph.D., medical oncologist at Stanford University Medical Center and the lead author of the Beyond BRCA study. “The ability to non-invasively characterize the molecular evolution of tumors during treatment using ctDNA can guide further investigation of treatment resistance.”

About Signatera


Signatera
 is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The test is available for clinical and research use, and in 2019, it was granted Breakthrough Device Designation by the FDA. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor. This maximizes accuracy for detecting the presence or absence of residual disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Unlike a standard liquid biopsy, Signatera is not intended to match patients with any particular therapy; rather, it is intended to detect and quantify how much cancer is left in the body, to detect recurrence earlier and to help optimize treatment decisions. Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Signatera has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

About Natera


Natera
 is a pioneer and global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, cancer researchers, biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com.

Follow Natera on LinkedIn

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, our expectations regarding the reliability, accuracy and performance of our tests, or regarding the benefits of our tests and product offerings to patients, providers and payers, or coverage and reimbursement determinations from third-party payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Paul Greenland, VP of Corporate Marketing, Natera, Inc., [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/natera-to-present-new-immunotherapy-monitoring-data-at-sabcs-2020-301188048.html

SOURCE Natera, Inc.